FDMT Q2 2020 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+64.5% YoY

Gross Profit

-$12M-332.7% margin

Operating Income

-$15M-417.0% margin

Net Income

-$15M-417.1% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+64.5%
Gross Profit	-$12M	-$6M	-92.3%
Operating Income	-$15M	-$9M	-73.6%
Net Income	-$15M	-$8M	-83.5%